Core Viewpoint - The stock of Giant Bio (02367) experienced a significant increase of over 12% due to a share buyback announcement, but subsequently fell by over 4% [1] Group 1: Share Buyback Announcement - Giant Bio announced plans to exercise its share buyback authorization, allowing the company to repurchase up to 103.6 million shares, which represents 10% of the issued shares excluding treasury shares [1] Group 2: Sales Performance - According to a report from Bank of America Securities, sales for the Co-Beauty brand during the Double Eleven shopping festival were under pressure, with sales on Tmall and Douyin declining by 20% and 50% year-on-year, respectively [1] - In contrast, the Co-Li Jin brand achieved positive growth during the same period [1] Group 3: Earnings Guidance - Management has revised down the earnings guidance for the year, expecting revenue to remain flat or slightly decline year-on-year, and has lowered the net profit forecast to a year-on-year decline in the mid to high single digits [1]
港股异动 | 巨子生物(02367)回落逾4% 美银称公司双十一期间销售受压 管理层下调业绩指引